$SMLR
Semler Scientific, Inc.

2020 Q4 Form 10-Q Financial Statement

#000110465920122514 Filed on November 06, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $12.07M $10.73M $8.902M
YoY Change 31.93% 20.5% 59.53%
Cost Of Revenue $986.0K $820.0K $974.0K
YoY Change 8.83% -15.81% 57.1%
Gross Profit $11.09M $9.907M $7.928M
YoY Change 34.47% 24.96% 59.84%
Gross Profit Margin 91.83% 92.36% 89.06%
Selling, General & Admin $4.431M $3.680M $4.200M
YoY Change -1.42% -12.38% 48.41%
% of Gross Profit 39.97% 37.15% 52.98%
Research & Development $660.0K $672.0K $617.0K
YoY Change -5.98% 8.91% 4.58%
% of Gross Profit 5.95% 6.78% 7.78%
Depreciation & Amortization $164.0K $32.00K $38.00K
YoY Change 1.23% -15.79% -68.33%
% of Gross Profit 1.48% 0.32% 0.48%
Operating Expenses $5.092M $3.680M $4.200M
YoY Change -2.02% -12.38% 23.17%
Operating Profit $5.995M $5.555M $3.111M
YoY Change 96.69% 78.56% 100.71%
Interest Expense $14.00K $2.000K -$2.000K
YoY Change 600.0% -200.0% -97.5%
% of Operating Profit 0.23% 0.04% -0.06%
Other Income/Expense, Net $442.0K $40.00K -$3.000K
YoY Change -7466.67% -1433.33%
Pretax Income $6.451M $5.595M $3.108M
YoY Change 111.93% 80.02% 111.43%
Income Tax $1.058M $729.0K -$4.671M
% Of Pretax Income 16.4% 13.03% -150.29%
Net Earnings $5.393M $4.866M $7.779M
YoY Change 90.36% -37.45% 429.18%
Net Earnings / Revenue 44.67% 45.36% 87.38%
Basic Earnings Per Share $0.74 $1.20
Diluted Earnings Per Share $663.7K $0.61 $0.96
COMMON SHARES
Basic Shares Outstanding 6.658M 6.579M 6.493M
Diluted Shares Outstanding 8.039M 8.108M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $22.08M $16.79M $8.542M
YoY Change 185.22% 96.59% 176.44%
Cash & Equivalents $22.08M $16.79M $8.542M
Short-Term Investments
Other Short-Term Assets $1.376M $1.530M $274.0K
YoY Change 537.04% 458.39% 61.18%
Inventory $340.0K
Prepaid Expenses $828.0K $900.0K
Receivables $2.808M $3.455M $3.271M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $26.60M $21.78M $12.09M
YoY Change 132.48% 80.18% 110.57%
LONG-TERM ASSETS
Property, Plant & Equipment $261.0K $258.0K $2.046M
YoY Change 4.82% -87.39% 58.6%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $3.051M
YoY Change
Other Assets $418.0K $432.0K $4.724M
YoY Change 2686.67% -90.86% 23520.0%
Total Long-Term Assets $8.036M $6.269M $6.770M
YoY Change 17.42% -7.4% 420.77%
TOTAL ASSETS
Total Short-Term Assets $26.60M $21.78M $12.09M
Total Long-Term Assets $8.036M $6.269M $6.770M
Total Assets $34.64M $28.05M $18.86M
YoY Change 89.42% 48.74% 167.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $677.0K $336.0K $669.0K
YoY Change 100.3% -49.78% 167.6%
Accrued Expenses $2.798M $4.277M $2.724M
YoY Change -28.51% 57.01% 20.53%
Deferred Revenue $963.0K $960.0K
YoY Change 0.84%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.514M $5.651M $4.747M
YoY Change -13.31% 19.04% 0.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $332.0K $345.0K $8.000K
YoY Change 4642.86% 4212.5% -20.0%
Total Long-Term Liabilities $332.0K $345.0K $8.000K
YoY Change 4642.86% 4212.5% -20.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.514M $5.651M $4.747M
Total Long-Term Liabilities $332.0K $345.0K $8.000K
Total Liabilities $4.846M $5.996M $4.755M
YoY Change -7.06% 26.1% 0.53%
SHAREHOLDERS EQUITY
Retained Earnings $7.673M $2.280M
YoY Change -221.14%
Common Stock $7.000K $7.000K
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares $25.00K $25.00K
Shareholders Equity $29.79M $22.05M $14.10M
YoY Change
Total Liabilities & Shareholders Equity $34.64M $28.05M $18.86M
YoY Change 89.42% 48.74% 167.86%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $5.393M $4.866M $7.779M
YoY Change 90.36% -37.45% 429.18%
Depreciation, Depletion And Amortization $164.0K $32.00K $38.00K
YoY Change 1.23% -15.79% -68.33%
Cash From Operating Activities $5.514M $3.542M $4.710M
YoY Change 51.69% -24.8% 313.16%
INVESTING ACTIVITIES
Capital Expenditures -$436.0K -$99.00K -$366.0K
YoY Change -11.02% -72.95% 74.29%
Acquisitions
YoY Change
Other Investing Activities $152.0K -$400.0K
YoY Change
Cash From Investing Activities -$284.0K -$499.0K -$366.0K
YoY Change -42.04% 36.34% 74.29%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 56.00K 104.0K 16.00K
YoY Change -101.42% 550.0% -88.57%
NET CHANGE
Cash From Operating Activities 5.514M 3.542M 4.710M
Cash From Investing Activities -284.0K -499.0K -366.0K
Cash From Financing Activities 56.00K 104.0K 16.00K
Net Change In Cash 5.286M 3.147M 4.360M
YoY Change -759.93% -27.82% 307.48%
FREE CASH FLOW
Cash From Operating Activities $5.514M $3.542M $4.710M
Capital Expenditures -$436.0K -$99.00K -$366.0K
Free Cash Flow $5.950M $3.641M $5.076M
YoY Change 44.24% -28.27% 276.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Registrant Name
EntityRegistrantName
Semler Scientific, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001554859
dei Trading Symbol
TradingSymbol
smlr
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36305
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
26-1367393
dei Entity Address Address Line1
EntityAddressAddressLine1
2340-2348 Walsh Avenue, Suite 2344
dei Entity Address City Or Town
EntityAddressCityOrTown
Santa Clara
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
95051
dei City Area Code
CityAreaCode
877
dei Local Phone Number
LocalPhoneNumber
774-4211
dei Security12b Title
Security12bTitle
N/A
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6658114
CY2020Q3 us-gaap Revenues
Revenues
10727000
CY2019Q3 us-gaap Revenues
Revenues
8902000
us-gaap Revenues
Revenues
26530000
us-gaap Revenues
Revenues
23616000
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
820000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
974000
us-gaap Cost Of Revenue
CostOfRevenue
2370000
us-gaap Cost Of Revenue
CostOfRevenue
2755000
CY2020Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
672000
CY2019Q3 us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
617000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
2277000
us-gaap Operating Costs And Expenses
OperatingCostsAndExpenses
1777000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2116000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2345000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7283000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6626000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1564000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1855000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4634000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4798000
CY2020Q3 us-gaap Costs And Expenses
CostsAndExpenses
5172000
CY2019Q3 us-gaap Costs And Expenses
CostsAndExpenses
5791000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3486000
us-gaap Costs And Expenses
CostsAndExpenses
16564000
us-gaap Costs And Expenses
CostsAndExpenses
15956000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
5555000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
3111000
us-gaap Operating Income Loss
OperatingIncomeLoss
9966000
us-gaap Operating Income Loss
OperatingIncomeLoss
7660000
CY2020Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
2000
CY2019Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
5000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
38000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
64000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
40000
CY2019Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
69000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
5595000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3108000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
10035000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
7657000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
729000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4671000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1421000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4594000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
4866000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
7779000
us-gaap Net Income Loss
NetIncomeLoss
8614000
us-gaap Net Income Loss
NetIncomeLoss
12251000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6578808
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6492501
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6553522
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6410588
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.07
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.51
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8038513
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8108053
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8046759
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8121996
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16793000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7741000
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
56000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
36000
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3455000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
15000
CY2020Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
3277000
CY2019Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
4501000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4277000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3914000
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
960000
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
955000
CY2020Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
78000
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1530000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
216000
CY2020Q3 us-gaap Assets Current
AssetsCurrent
21778000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
11443000
CY2020Q3 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
1802000
CY2019Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
2079000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
258000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
249000
CY2020Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
500000
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
432000
CY2020Q3 us-gaap Assets
Assets
28047000
CY2019Q4 us-gaap Assets
Assets
18287000
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
336000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
338000
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5651000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5207000
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
345000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7000
CY2020Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
345000
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
7000
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6640833
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6556221
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6615833
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6531221
CY2020Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
25000
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
25000
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
7000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
7000
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19764000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
19400000
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
2280000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6334000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
22051000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13073000
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28047000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18287000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
6221000
CY2019Q3 smlr Warrant Exercises
WarrantExercises
0
CY2020Q3 us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
0
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
104000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
62000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
4866000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
22051000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
13073000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
16000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
86000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
7779000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
14102000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
17019000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4196000
smlr Adjustments To Additional Paid In Capital Warrant Repurchase
AdjustmentsToAdditionalPaidInCapitalWarrantRepurchase
2687000
smlr Warrant Exercises
WarrantExercises
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
60000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
282000
us-gaap Net Income Loss
NetIncomeLoss
12251000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
14102000
us-gaap Stock Issued During Period Value Employee Stock Ownership Plan
StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan
0
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
174000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
190000
us-gaap Net Income Loss
NetIncomeLoss
8614000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
22051000
us-gaap Net Income Loss
NetIncomeLoss
8614000
us-gaap Net Income Loss
NetIncomeLoss
12251000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
412000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
470000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
1224000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-4709000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-178000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-159000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
43000
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
42000
us-gaap Share Based Compensation
ShareBasedCompensation
190000
us-gaap Share Based Compensation
ShareBasedCompensation
282000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
512000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1315000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
122000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
416000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
389000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
264000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
109000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
5000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
734000
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
416000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
9600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
9093000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
103000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
106000
us-gaap Payments To Acquire Notes Receivable
PaymentsToAcquireNotesReceivable
400000
us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
219000
us-gaap Payments To Acquire Equipment On Lease
PaymentsToAcquireEquipmentOnLease
1102000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-722000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1208000
us-gaap Payments For Repurchase Of Warrants
PaymentsForRepurchaseOfWarrants
2687000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
174000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
60000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
174000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2627000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
9052000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
5258000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7741000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3284000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16793000
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
8542000
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">1.           </b><b style="font-weight:bold;">Basis of Presentation</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">Semler Scientific, Inc., a Delaware corporation (“Semler” or “the Company”), prepared the unaudited interim financial statements included in this report in accordance with United States generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 9, 2020 (the “Annual Report”). In the opinion of management, these financial statements include all adjustments (consisting of normal recurring adjustments) necessary for a fair statement of the financial position, results of operations and cash flows for the periods presented. The results of operations for the interim periods shown in this report are not necessarily indicative of the results that may be expected for any future period, including the full year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">On January 30, 2020, the World Health Organization (“WHO”) declared the recent novel coronavirus (COVID-19) outbreak a global health emergency, which prompted national, state and local governments to begin putting actions in place to slow the spread of COVID-19. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic. The outbreak of COVID-19 resulted in travel restrictions, quarantines, “stay-at-home” and “shelter-in-place” orders and extended shutdown of certain businesses around the world. While restrictions began to ease in the second quarter and activities began to resume, recent outbreaks could lead to restrictions being reimplemented. For the nine months ended September 30, 2020, the Company’s revenues, primarily from variable-fee licenses, were negatively impacted by the COVID-19 pandemic. For the three months ended September 30, 2020, the Company’s revenues, primarily from variable-fee licenses, rebounded to and even exceeded pre-COVID-19 levels. The extent and duration of the pandemic is unknown, and the future effects on the Company’s business are uncertain and difficult to predict. The Company is continuing to monitor the events and circumstances surrounding the COVID-19 pandemic, which may require adjustments to the Company’s estimates and assumptions in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Recently Issued Accounting Pronouncements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounting Pronouncements Recently Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In November 2019, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2019-08 – <i style="font-style:italic;">Compensation – Stock Compensation (Topic 718) and Revenue from Contracts with Customer (Topic 606)</i>.  The amendments on this update require that an entity measure and classify share-based payment awards granted to a customer by applying the guidance in Topic 718.  The amount recorded as a reduction in the transaction price should be based on the grant-date fair value of the share-based payment award.  This standard is effective for the Company’s annual periods beginning after December  15, 2019, including interim periods within those fiscal years. The Company adopted the new standard on January 1, 2020 and determined that the adoption of this new accounting guidance did not have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In June 2018, the FASB issued ASU No. 2018-07, <i style="font-style:italic;">Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</i>. This ASU expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and services from nonemployees. An entity should apply the requirements of Topic 718 to nonemployee awards except for specific guidance on inputs to an option pricing model and the attribution of costs. The ASU specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. This standard is effective for the Company’s annual periods beginning after December 15, 2019, including interim periods within those fiscal years. The Company adopted the new standard on January 1, 2020 and determined that the adoption of this this new accounting guidance did not have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In August 2018, the FASB issued ASU No. 2018-13, <i style="font-style:italic;">Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement</i>. The amendments in this ASU modify the disclosure requirements on fair value measurements removing the requirements to disclosure amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, the policy for timing of transfers between levels, and the valuation processes for Level 3 fair value measurements. In addition, it modified certain disclosures related to Level 3 fair value measurements and added additional disclosures regarding the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements and the changes in unrealized gains and losses for the period included in other comprehensive income for recurring Level 3 fair value measurements held at the end of the reporting period. This update is effective for the Company’s annual periods beginning after December 15, 2019, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">including interim periods within those fiscal years. The Company adopted the new standard on January 1, 2020 and determined that the adoption of this this new accounting guidance did not have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><i style="font-style:italic;">Accounting Pronouncements Not Yet Adopted</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In June 2016, the FASB issued ASU No. 2016-13, <i style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“Topic 326”)</i>. This ASU requires timelier recording of credit losses on loans and other financial instruments held. Instead of reserves based on a current probability analysis, Topic 326 requires the measurement of all expected credit losses for financial assets held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. All organizations will now use forward-looking information to better inform their credit loss estimates. Topic 326 requires enhanced disclosures regarding significant estimates and judgments used in estimating credit losses, as well as the credit quality and underwriting standards of an organization’s portfolio. These disclosures include qualitative and quantitative requirements that provide information about the amounts recorded in the financial statements. In addition, Topic 326 amends the accounting for credit losses on available-for-sale debt securities and purchased financial assets with credit deterioration. In April 2019, the FASB issued ASU No. 2019-04, <i style="font-style:italic;">Codification Improvements to Topic 326 Financial Instruments—Credit Losses, Topic 815, Derivatives and Hedging, and Topic 825, Financial Instruments</i>, to introduce amendments which will affect the recognition and measurement of financial instruments, including derivatives and hedging. In May 2019, the FASB issued ASU No. 2019-05, <i style="font-style:italic;">Financial Instruments – Credit Losses (Topic 326); Targeted Transition Relief</i>. The amendments in this ASU provide entities that have certain instruments within the scope of Subtopic 326-20 with an option to irrevocably elect the fair value option in Subtopic 825-10, applied on an instrument-by-instrument basis for eligible instruments upon adoption of Topic 326. This standard and related amendments are effective for the Company’s fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2023. The Company does not anticipate this new standard will have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In December 2019, the FASB issued ASU No. 2019-12, <i style="font-style:italic;">Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes</i>, which simplifies the accounting for income taxes by removing certain exceptions to the general principles for income taxes. This update is effective for the Company’s annual periods beginning after December 15, 2020, including interim periods within those fiscal years. The Company will adopt the new standard in the first quarter of fiscal year 2021. The Company does not anticipate this update will have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In January 2020, the FASB issued ASU No. 2020-01, <i style="font-style:italic;">Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815)</i>. The amendments in this ASU clarify the interaction between the accounting for investments in equity securities, investment in equity method and certain derivatives instruments. The ASU is expected to reduce diversity in practice and increase comparability of the accounting for these interactions. This ASU is effective for fiscal years beginning after December 15, 2021. The adoption of this ASU is not expected to have any impact on the Company's results of operations, cash flows or financial position.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In March 2020, FASB issued ASU No. 2020-03, <i style="font-style:italic;">Codification Improvements to Financial Instruments</i>. This ASU improves and clarifies various financial instruments topics, including the current expected credit losses standard issued in 2016 (ASU No. 2016-13). The ASU includes seven different issues that describe the areas of improvement and the related amendments to GAAP, intended to make the standards easier to understand and apply by eliminating inconsistencies and providing clarifications. The amendments have different effective dates. The Company is evaluating the effect of adopting this new accounting guidance, but does not expect adoption will have a material impact on its financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In March 2020, the FASB issued ASU No. 2020-04, <i style="font-style:italic;">Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</i>. This ASU provides optional expedient and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. In response to the concerns about structural risks of interbank offered rates and, particularly, the risk of cessation of the London Interbank Offered Rate, regulators in several jurisdictions around the world have undertaken reference rate reform initiatives to identify alternative reference rates that are more observable or transaction-based and less susceptible to manipulation. The ASU provides companies with optional guidance to ease the potential accounting burden associated with transitioning away from reference rates that are expected to </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">be discontinued. The ASU can be adopted no later than December 1, 2022, with early adoption permitted. The Company has not yet adopted this ASU and is evaluating the effect of adopting this new accounting guidance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:1pt;margin-bottom:10pt;visibility:hidden;">​</span></p>
CY2020Q3 smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
4088000
CY2019Q3 smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
2660000
smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
7080000
smlr Revenue Recognition From Variable License Fee Contracts
RevenueRecognitionFromVariableLicenseFeeContracts
6166000
CY2020Q3 smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
332000
CY2019Q3 smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
291000
smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
732000
smlr Revenue Recognition From Sales Of Hardware And Equipment Accessories
RevenueRecognitionFromSalesOfHardwareAndEquipmentAccessories
842000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6307000
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5951000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18718000
CY2019Q4 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
3374000
CY2020Q3 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
1470000
CY2019Q4 us-gaap Capital Leases Lessee Balance Sheet Assets By Major Class Accumulated Deprecation
CapitalLeasesLesseeBalanceSheetAssetsByMajorClassAccumulatedDeprecation
1295000
CY2020Q3 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
1802000
CY2019Q3 smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
38000
smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
143000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16608000
CY2020Q3 us-gaap Capital Leased Assets Gross
CapitalLeasedAssetsGross
3272000
CY2019Q4 us-gaap Capital Leases Balance Sheet Assets By Major Class Net
CapitalLeasesBalanceSheetAssetsByMajorClassNet
2079000
CY2020Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
146000
CY2019Q3 us-gaap Depreciation Nonproduction
DepreciationNonproduction
124000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
318000
us-gaap Depreciation Nonproduction
DepreciationNonproduction
361000
CY2020Q3 smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
56000
smlr Accumulated Depreciation Reduction For Returned Items
AccumulatedDepreciationReductionForReturnedItems
115000
CY2020Q3 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-54000
CY2019Q3 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-62000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-178000
us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-159000
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
739000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
636000
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
481000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
387000
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
258000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
249000
CY2020Q3 us-gaap Depreciation
Depreciation
32000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
21000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
85000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
87000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
90000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
93000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
71000
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
447000
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
28000
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
419000
CY2020Q3 smlr Operating Lease Expense In Excess Of Cash Payments
OperatingLeaseExpenseInExcessOfCashPayments
-7000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
412000
CY2019Q3 us-gaap Depreciation
Depreciation
38000
us-gaap Depreciation
Depreciation
94000
us-gaap Depreciation
Depreciation
109000
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2953000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2803000
CY2020Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
875000
CY2019Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
378000
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
449000
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
733000
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4277000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3914000
CY2020Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
32000
CY2019Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
17000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
67000
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
51000
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1581582
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.23
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y10M9D
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
70827000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
85226
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.77
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1496356
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.25
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y1M24D
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
75023000
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1447502
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.14
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y29D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
72741000
CY2020Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
244000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P0Y8M12D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
86000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
190000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
282000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
62000
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
86000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
190000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
282000
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1521264
us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8046759
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
8614000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.07
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8121996
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
12251000
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.51
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2019Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
0
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1319
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.1417
CY2019Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.50
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.60
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2019Q3 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6578808
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
4866000
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.74
CY2019Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6492501
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
7779000
CY2019Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.20
CY2020Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
70291
CY2020Q3 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2019Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
155490
CY2019Q3 smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
CY2020Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1389414
CY2020Q3 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2019Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1460062
CY2019Q3 us-gaap Amount Of Dilutive Securities Stock Options And Restrictive Stock Units
AmountOfDilutiveSecuritiesStockOptionsAndRestrictiveStockUnits
0
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8038513
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
4866000
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.61
CY2019Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8108053
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
7779000
CY2019Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.96
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6553522
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
8614000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.31
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
6410588
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
12251000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.91
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
69682
smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
190144
smlr Amount Of Dilutive Securities Common Stock Warrants
AmountOfDilutiveSecuritiesCommonStockWarrants
0
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
1423556
CY2020Q3 smlr Purchase Of Product Inventory
PurchaseOfProductInventory
1200000
CY2020Q3 smlr Distribution Agreement Renewal Term
DistributionAgreementRenewalTerm
P4Y
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
900000
CY2020Q3 us-gaap Notes And Loans Receivable Net Noncurrent
NotesAndLoansReceivableNetNoncurrent
500000
CY2020Q3 us-gaap Notes Issued1
NotesIssued1
400000
CY2020Q3 smlr Retention Of Expense
RetentionOfExpense
100000
CY2020Q3 us-gaap Debt Instrument Interest Rate Stated Percentage
DebtInstrumentInterestRateStatedPercentage
0.10
CY2020Q3 smlr Payments Receive On Note During Remainder Of020
PaymentsReceiveOnNoteDuringRemainderOf020
0
CY2020Q3 smlr Payment Of Note And Interest Upon Maturity In2021
PaymentOfNoteAndInterestUponMaturityIn2021
550000

Files In Submission

Name View Source Status
0001104659-20-122514-index-headers.html Edgar Link pending
0001104659-20-122514-index.html Edgar Link pending
0001104659-20-122514.txt Edgar Link pending
0001104659-20-122514-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
smlr-20200930.xsd Edgar Link pending
smlr-20200930x10q.htm Edgar Link pending
smlr-20200930x10q_htm.xml Edgar Link completed
smlr-20200930xex31d1.htm Edgar Link pending
smlr-20200930xex31d2.htm Edgar Link pending
smlr-20200930xex32d1.htm Edgar Link pending
smlr-20200930_cal.xml Edgar Link unprocessable
smlr-20200930_def.xml Edgar Link unprocessable
smlr-20200930_lab.xml Edgar Link unprocessable
smlr-20200930_pre.xml Edgar Link unprocessable